{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:32Z","timestamp":1790162132053,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technical University of Munich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AUO"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T04:42:42Z","timestamp":1544157762000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)"],"prefix":"10.1016","volume":"107","author":[{"given":"Margitta","family":"Retz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-4446","authenticated-orcid":false,"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Leiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogu","family":"Teber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"van Alphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart","family":"Beeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-2504","authenticated-orcid":false,"given":"Jan","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Indorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.11.001_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOU.0000000000000466","article-title":"Immunotherapy for kidney cancer: status quo and the future","volume":"28","author":"Bedke","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ejca.2018.11.001_bib2","series-title":"Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 1.2","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)","year":"2017"},{"key":"10.1016\/j.ejca.2018.11.001_bib3","series-title":"Guidelines on renal cell carcinoma","author":"Ljungberg","year":"2016"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.11.001_bib4","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"Eur Urol"},{"issue":"Suppl 15","key":"10.1016\/j.ejca.2018.11.001_bib6","doi-asserted-by":"crossref","first-page":"TPS4591","DOI":"10.1200\/jco.2013.31.15_suppl.tps4591","article-title":"Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced\/metastatic renal cell carcinoma (SWITCH-2 study)","volume":"31","author":"Gschwend","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.11.001_bib7","first-page":"v605","article-title":"IMmotion150: novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"28","author":"Powles","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.11.001_bib10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.11.001_bib11","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.11.001_bib12","doi-asserted-by":"crossref","first-page":"v295","DOI":"10.1093\/annonc\/mdx371","article-title":"Phase III randomized sequential, open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced\/metastatic renal cell carcinoma","volume":"28","author":"Retz","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.11.001_bib15","unstructured":"Common terminology criteria for adverse events (CTCAE) version 4.0 published: May 28, 2009 (v4.03: June 14, 2010) U.S. Department of health and human services, National Institutes of Health, National Cancer Institute Available at: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"10.1016\/j.ejca.2018.11.001_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation Health","volume":"1","author":"Webster","year":"2003","journal-title":"Qual Life Outcomes"},{"key":"10.1016\/j.ejca.2018.11.001_bib17","first-page":"191","article-title":"Development and validation of the functional assessment of cancer therapy kidney symptom index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib18","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/j.1464-410X.2011.10186.x","article-title":"Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicenter retrospective analysis of 189 patient cases","volume":"108","author":"Porta","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2018.11.001_bib19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2018.11.001_bib20","doi-asserted-by":"crossref","first-page":"v295","DOI":"10.1093\/annonc\/mdx371.002","article-title":"A Phase 1b\/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. NCT02501096. ESMO 2017","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 6S","key":"10.1016\/j.ejca.2018.11.001_bib23","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.ejca.2018.11.001_bib24","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma patients of atezolizumab and bevacizumab vs and following atezolizumab or sunitinib","volume":"35","author":"Atkins","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.001_bib25","unstructured":"NCT0 2811861: a multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma."},{"key":"10.1016\/j.ejca.2018.11.001_bib26","unstructured":"NCT02959554 study in which therapy is either switched to nivolumab after 3 months of treatment or therapy is continued with a tyrosine kinase inhibitor in patients with metastatic renal cell carcinoma (RCC) and disease control, Gr\u00fcnwald, Hannover."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T01:39:10Z","timestamp":1605577150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918314540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":26,"alternative-id":["S0959804918314540"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}